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Summary 
 
After cell hijacking and intracellular amplification, nonlytic enveloped viruses are 
usually released from the infected cell by budding across internal membranes or 
through the plasma membrane. The enveloped human hepatitis B virus (HBV) is an 
example of virus using an intracellular compartment to form new virions. Four 
decades after its discovery, HBV is still the primary cause of death by cancer due to a 
viral infection worldwide. Despite numerous studies on HBV genome replication little 
is known about its morphogenesis process. In addition to viral neogenesis, the HBV 
envelope proteins have the capability without any other viral component to form 
empty subviral envelope particles (SVP) which are secreted into the blood of infected 
patients. A better knowledge of this process may be critical for future antiviral 
strategies. Previous studies have speculated that the morphogenesis of HBV and its 
SVP occur through the same mechanisms. However recent data clearly suggest that 
two different processes, including constitutive Golgi pathway or cellular machinery 
that generates internal vesicles of multivesicular bodies (MVB), independently form 
these two viral entities. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The human hepatitis B virus (HBV) is a small hepatotropic and highly infectious 
DNA virus member of the Hepadnaviridae family. HBV represents the prototype virus 
of the Orthohepadnavirus genus. Discovered almost forty years ago (Dane et al., 
1970; Blumberg et al., 1965), HBV still remains a major health problem worldwide, as 
there is no widely available treatment for the estimated 350 million chronic carriers 
who have a high risk of liver cirrhosis or cancer. Despite the existence of an effective 
vaccine designed more than twenty years ago, currently almost 1 million people per 
year die due to HBV infection (Perz et al., 2006). A thorough understanding of HBV 
structure and morphogenesis is thus promptly required for the development of 
innovative antiviral treatment. 
 
The infectious HBV virion (or Dane particle) is a spherical particle, 42 nm in 
diameter, consisting of an icosahedral capsid about 30 nm in diameter. The virion 
contains the circular partially double-strand genomic DNA about 3.2 kb in length 
which is covalently linked to the viral reverse-transcriptase. This nucleocapsid is 
surrounded by a lipid bilayer in which the three envelope proteins (small [S], medium 
[M] and large [L]) are anchored as transmembrane proteins playing a major role in 
HBV morphogenesis and infectivity (Bruss, 2007). After being delivered into the 
nucleus (Rabe et al., 2003), the viral DNA is converted to a covalently closed circular 
DNA (cccDNA) which is transcribed in : (i) pregenomic RNA (pgRNA) about 3.5 kb in 
length and (ii) different subgenomic RNAs encoding all the viral proteins necessary 
for the HBV replication cycle (Beck and Nassal, 2007). In the cytosol, a single 
molecule of pgRNA together with the viral reverse transcriptase is incorporated into 
an assembling capsid. Once the pgRNA is encapsidated, reverse-transcription into a 
new genomic DNA occurs (Beck and Nassal, 2007). The mature nucleocapsid is then 
enveloped by the surface proteins and a new generation of infectious virions can be 
released (Bruss, 2007). Interestingly, the production of the HBV surface proteins also 
leads to the intracellular budding of empty subviral spherical or filamentous envelope 
particles (SVP). SVP are 20 nm in diameter, lack the nucleocapsid and are secreted 
in great excess over virions (Ganem, 1991; Heermann et al., 1984). It has been 
clearly shown that this natural phenomenon specific to HBV is linked to the ability of 
the S envelope protein to spontaneously form empty envelope particles at the rough 
endoplasmic reticulum (ER) (Dubois et al., 1980). This noninfectious material is 
currently the basis of most vaccines against hepatitis B (Eddleston, 1990). 
Unfortunately, despite in vitro production of virions using HBV DNA transfection of 
Huh-7 or HepG2 cells (Yaginuma et al., 1987; Sureau et al., 1986) or HBV infection 
of the recently developed HepaRG cell line (Gripon et al., 2002), HBV 
morphogenesis remains highly difficult to observe by electron microscopy (EM). This 
may be due to the low rate of HBV production approaching 1 to 10 viruses per 
hepatocyte per day in vivo (Nowak et al., 1996). Thus, the models of HBV and its 
subviral envelope particles morphogenesis are based on biochemical approaches 
(Huovila et al., 1992) and lack ultrastructural data that may be helpful for a more 
complete understanding of these mechanisms, as for other viral models (Roingeard, 
2008). In this review, we focus on data that have recently been accumulated on both 
HBV and SVP morphogenesis and illustrate our discussion with new and original EM 
observations. 
 
HBV capsid 
 
The 22 kD HBV core protein (also called C or HBc) consists of 183 or 185 
amino acid (aa) residues depending on the genotype and is relatively well-conserved 
among HBV isolates (Chain and Myers, 2005). In the cytosol, the fundamental 
building unit of the HBV capsid is formed by homodimerization of two core proteins 
stabilized by a disulfide bridge between their respective Cys-61 residues (Zheng et 
al., 1992; Zhou and Standring, 1992). Then, dimer oligomerization occurs by unclear 
cellular processes and leads to the formation of two different types of capsids : (i) a 
capsid consisting of 90 dimers associated in an icosahedral symmetry (T = 3) about 
30 nm in diameter and (ii) a larger capsid consisting of 120 dimers associated in an 
icosahedral symmetry (T = 4) about 34 nm in diameter (Wynne et al., 1999). Both 
capsids are found in infected cells but the T = 4 capsids seem to be preferentially 
selected for envelopment in infectious particles (Roseman et al., 2005). However T = 
3 capsids have also been reported to be incorporated in virions in various 
percentages (Dryden et al., 2006; Roseman et al., 2005). While the N-terminus of the 
capsid protein is important for the dimerization process, the basic C-terminal domain 
contains a nuclear localization sequence (NLS) and an Arg-enriched area. Formed by 
the last 34 aa, this basic area is probably involved in the pgRNA / reverse-
transcriptase complex encapsidation (Nassal, 1992; Gallina et al., 1989). Finally, the 
HBV core protein structure was solved by crystallization at a resolution of 3.3 Å 
(Wynne et al., 1999). In a recent review, Bruss described the HBV core dimer as a 
structure resembling an upside down “T” ; with the horizontal bar mediating the inter-
dimer association (Bruss, 2007). The perpendicular domain to this bar consists of a 
spike formed by 4 -helices, 1 -helical hairpin for each protein, protruding outwards 
from the center of the dimer basis (Wynne et al., 1999). The sequence from residue 
78 to residue 83, located on the top of the spike, is known as the major epitope of the 
capsid antigen (HBcAg). Associations of 5 or 6 dimers are arranged around the 12 
axes with a five-fold or two-fold (or quasi six-fold) symmetry, respectively. Finally, 
analysis by cryo-electron microscopy (cryo-EM) showed that the capsid was not 
continuous but opened by the presence of pores about 12 to 15 Å in diameter 
(Wynne et al., 1999). It was suggested that these pores are essential to enable the 
entry of deoxyribonucleotides during the genomic DNA synthesis and / or the 
expulsion of ribonucleotides after the degradation of the pgRNA by the RNaseH 
activity of the reverse transcriptase. 
 
As described above, all stages of pgRNA reverse-transcription occur in the 
nucleocapsid. However, only virions containing a mature circular partially double-
strand genomic DNA are secreted into the extracellular environment (Weiser et al., 
1983; Mason et al., 1982). Actually, it has been suggested that the presence of the 
pgRNA could interfere with the incorporation of the nucleocapsid in the virion. The 
synthesis of genomic DNA would be required and associated with structural changes 
in the capsid structure leading to a mature nucleocapsid formation capable of being 
wrapped by the viral envelope (Summers and Mason, 1982). Recently, Roseman et 
al were able to support this hypothesis by demonstrating a structural difference 
between a pgRNA-containing capsid and a genomic DNA-containing capsid. The 
difference is related to the contact force generated by a double-strand nucleic acid on 
a hydrophobic pocket located at the junction between the spike and the basis of the 
dimer (Roseman et al., 2005). This pressure would make the pocket accessible to the 
HBV surface proteins in order to proceed to the nucleocapsid / envelope interaction. 
Interestingly, the natural mutation I97L found in the “adr” HBV subtype leads to the 
early envelopment of an immature single-strand DNA-containing nucleocapsid which 
can be corrected by the P130T point mutation (Yuan and Shih, 2000). In addition, the 
high infectivity of HBV could be explained by the existence of a quasi-control and/or a 
strict selection for mature nucleocapsid envelopment and new infectious virions 
secretion. As a typical example, the duck hepatitis B virus (DHBV, genus 
Avihepadnavirus) production rate is about 1 infectious virion per physical particle 
secreted (Jilbert et al., 1996). 
 
HBV envelope 
 
The three envelope proteins S, M and L are encoded by a single open reading 
frame referred as ORF-E, 389 or 400 codons in length depending on the “ay” or “ad” 
viral subtype, respectively. This ORF consists of three 5’ in-phase ATG codons for 
the initiation of translation and one 3’ TAA termination codon. Thus, the three HBV 
envelope proteins only differ by the length of their N-terminal domains. These 
envelope proteins are present in different proportions in the three types of HBV-
related particles : while the S protein represents the major component of the viral 
envelope, the L protein is only found in the virion and the filamentous SVP 
(Heermann et al., 1984). The M distribution seems to be the same in all particles. 
 
The 226 aa S protein is a typical membrane protein with a relatively complex 
topology and is produced at the rough endoplasmic reticulum (ER) (Bruss, 2007). 
Computer modeling of its secondary structure suggests that three hydrophobic 
integral domains are separated by two hydrophilic loops. The S protein is 
translocated at the ER compartment by its N-terminal first transmembrane domain 
(TM-I) located between residues 4 to 24. The fact that this sequence is not cleaved 
by any of the cellular signal peptidases allows its co-translational translocation 
through the ER membrane in order to direct the N-terminus of the protein into the ER 
lumen. Downstream of this TM-I domain is a cytosolic loop (CYL-1) followed by a 
second transmembrane domain (TM-II) located between residues 80 to 100 which 
acts as a type II signal/anchor domain. The TM-II C-terminal end directs a luminal 
loop known as the antigenic loop (AGL) containing a single N-glycosylation site at 
Asn-146 (Peterson et al., 1982). The prediction models for the third C-terminal 
hydrophobic domain show that this region is actually composed of two 
transmembrane -helices TM-III and IV, composed of residues 173 to 193 and 202 to 
222 respectively that are separated by a short cytosolic sequence (CYL-2) (Persson 
and Argos, 1994). The arrangement of these two helices in the ER membrane is 
probably responsible for the translocation of the C-terminus of S into the ER lumen 
(Sonveaux et al., 1994). Since S contains fourteen Cys residues some of which are 
directly involved in disulfide bridge formation and/or particle secretion, it is clear that 
the acquisition of a functional structure must be extremely regulated (Mangold and 
Streeck, 1993). Therefore, as with many other transmembrane proteins, the co and 
post-translational modifications of S are highly monitored by ER chaperones such as 
the protein disulfide isomerase (PDI) (Helenius and Aebi, 2001; Huovila et al., 1992). 
Several other chaperones are likely involved in this control but still remain undefined. 
The fact that only half of the small envelope proteins are found N-glycosylated in the 
particles clearly emphasizes the complexity of its maturation (Peterson et al., 1982). 
The S protein is an unusual viral surface protein in the sense that it is the necessary 
and sufficient unit for the formation and the spontaneous budding of HBV subviral 
envelope particles (SVP), in the absence of any other viral factor. Indeed, in vitro 
production of S alone results in the secretion of empty and non-infectious spherical 
SVP which are currently industrially produced to generate highly efficient and safe 
vaccines against HBV (Eddleston, 1990; Dubois et al., 1980). Additionally, it is widely 
accepted that the oligomerization of several S proteins is required to initiate the SVP 
morphogenesis (Huovila et al., 1992). The exclusion of any other cellular proteins 
and even envelope proteins from avian hepadnaviruses during this process suggests 
a specific control of the SVP formation and composition (Gerhardt and Bruss, 1995; 
Stibbe and Gerlich, 1982). 
 
The biosynthesis of the 281 aa M protein is quite similar to S. This protein 
differs from S by the N-terminal addition of a 55 residue sequence named “preS2” 
which is co-translationally translocated into the ER lumen by the TM-I signal 
sequence (Eble et al., 1990). In addition to the Asn-201 (Asn-146 on the S protein), 
the preS2 domain contains an N-glycosylation site at Asn-4 together with an optional 
O-glycosylation site at Thr-37 depending on the genotype (Tolle et al., 1998; 
Heermann et al., 1984). Interestingly, a strict correlation between glycan-dependent 
chaperone binding and secretion of M indicates that ER proteins such as calnexin 
promote folding and trafficking of M allowing particle secretion (Werr and Prange, 
1998). However, the exact role of M in the viral cycle remains unclear. Indeed, its in 
vivo absence in infected cells does not disrupt viral morphogenesis or particle 
functionality (Fernholz et al., 1991). Thereby, this protein seems not to be essential 
for virus spread and its complete absence from the Avihepadnavirus genomes 
reinforces this hypothesis. 
 
The L protein is characterized by the addition of a 108 to 119 residue sequence 
named “preS1” on the N-terminus of M. Thus, this large protein basically incorporates 
the preS domain (preS1 and preS2) to the N-terminus of S. Although this has not 
been demonstrated experimentally, the N-terminus of preS1 is probably anchored on 
the ER surface by a fourteen carbon saturated fatty acid added by myristylation at 
Gly-2 (Persing et al., 1987). The kinetics of this biochemical modification and its 
exact role for the virus life cycle are still unclear but cellular enzymes such as the 
cytosolic N-myristyl transferase are probably involved in this process. Contrary to the 
M protein, the L protein is only N-glycosylated at Asn located in the S domain (Bruss, 
2007). Two other potential sites of N-glycosylation are also present at Asn-15 of the 
preS1 domain and Asn-4 of the preS2 domain but are not glycosylated because of 
their cytosolic localization (Heermann et al., 1984). Indeed, it seems that initially the 
N-terminus of L is retained in the cytosol as an internal preS domain in a topology 
called “i-preS” (Bruss, 2007). The translocation of the preS domain into the ER lumen 
occurs in an obscure but probably post-translational mechanism leading to an 
external topology of L called “e-preS”. This dual orientation of L is physically linked to 
the ER membrane, suggesting the involvement of host-cell transmembrane transport 
machinery. However, an interesting computer-aided analysis suggests that 
oligomerized S domains could form a channel in the ER membrane for the preS 
transport (Berting et al., 1995). In parallel, some studies led to the identification of a 
topogenic element mapped to a preS1 C-terminal sequence located between 
residues 70 and 94, termed cytosolic anchorage determinant (CAD). CAD interacts 
with the cognate heat-shock protein Hsc-70 preventing preS co-translational 
translocation into an “e-preS” topology and glycosylation of the Asn-15 and Asn-4 of 
the preS1 and preS2 domains, respectively (Lambert and Prange, 2003; Loffler-Mary 
et al., 1997). Luminal chaperones binding to the e-preS domain such as the binding 
protein BiP could support this process (Cho et al., 2003). Currently, it is clearly 
recognized that both “i-preS” and “e-preS” topologies of L play a specific role in the 
viral cycle : recruitment of a mature viral nucleocapsid for virion budding (Bruss, 
2007) and recognition of the cellular (co-)receptor(s) for virus entry (Glebe and 
Urban, 2007), respectively. 
 
SVP morphogenesis 
 
As described above, the HBV surface proteins are not only incorporated into the 
virion envelope but also bud in an empty and non-infectious subviral envelope 
particle (SVP). The SVP conformation is organized as an octahedral sphere about 20 
nm in diameter containing 48 S-dimer subunits or as a filament with the same 
diameter but with variable length (Gilbert et al., 2005). This variation in the particle 
topology seems to greatly depend on the L protein quantity and on the S/L ratio 
incorporated into the particle during the morphogenesis process. Thus, since the 
spherical SVP are essentially composed by the S protein, the filament organization is 
greatly dependent on the co-assembly of a large proportion of L protein together with 
S (Heermann et al., 1984). During the infection, it is currently assumed that these 
SVP act as decoys, trapping the host’s immune system to protect the infectious virus. 
However, a high proportion of L protein tends to retain the particles inside the 
infected cell because of specific retention motifs (Persing et al., 1986). Therefore, the 
inability of infected cells to export long HBV filamentous particles through the cellular 
secretion pathway seems to be at the origin of a direct cytopathic effect described as 
an inclusive cellular vesicle called “ground-glass” structure (Roingeard and Sureau, 
1998). 
 
How the SVP formation occurs in the cell is still highly debated, but recent 
ultrastructural observations of cells producing the small S protein alone have 
provided a better understanding of this particular question (Patient et al., 2007). The 
structural unit of the SVP is a block composed by a strongly associated dimer of S 
protein (Gilbert et al., 2005), and this dimer is probably stabilized by disulfide bridges 
which are generated under the control of the ER chaperone PDI (Huovila et al., 
1992). The S protein self-assembles initially in a filamentous form within the 
perinuclear space which is part of the ER of the cell (Fig 1A-a). These filaments are 
then clustered and packed into crystal-like structures and transferred by ER-derived 
vesicles to the rough ER-Golgi intermediate compartment (ERGIC) (Fig 1A-b). 
Unfortunately, the mechanisms and the cellular factors favoring all these events are 
not yet understood. In higher eukaryotes, transport from the ER is initiated by a COP-
II-mediated budding of vesicular carriers through a specialized subdomain of the ER 
named ER-exit sites (ERES) (Appenzeller-Herzog and Hauri, 2006). Theorically the 
directionality of vesicle transit from one cellular compartment to another is dependent 
on a motor/cytoskeletal network including microtubule-plus-end-directed kinesin 
and/or microtubule-minus-end-directed dynein. However, as ERGIC clusters are 
close to but clearly distinct from ERES, ER to ERGIC transports are known to be 
microtubule-independent. The ER-derived vesicles containing the S filaments are 
then transported to the ERGIC where the membrane docking is probably mediated by 
tethering proteins such as p115, a Rab1 effector, and followed by a SNARE-
mediated membrane fusion. Once unleashed into the ERGIC lumen, the filaments 
are unpacked and relaxed possibly due to a different cellular milieu and/or 
association with new chaperones (Fig 1A-c), before being converted into spherical 
particles for secretion (Fig 1A-d). This hypothesis is supported by the observation 
that S secreted particles produced in a transgenic mouse model show a significant 
heterogeneity in size, a phenomenon that may be linked to the dissociation of 
filamentous particles (Gilbert et al., 2005). Despite the lack of information indicating a 
specific release pathway of spherical SVP from the ERGIC, the conversion of the N-
linked glycans on the S protein into complex structures before exocytosis provides 
arguments for the export of the particles using a constitutive cellular secretory 
pathway through the Golgi appartus (Patzer et al., 1986). In all cases, COP-I and the 
Arf family of small GTPases may be involved. 
 
While our understanding of the SVP formation and traffic has progressed, the 
early mechanisms of their assembly remain unclear. To illustrate this review, we have 
re-examined cells producing the HBV S protein by EM, paying particular attention to 
the perinuclear space, to identify the events that precede the budding of vesicles 
containing packed filaments (Fig 1B). This observation suggests that the filaments 
increase progressively in size and number and initially induce a slight dilatation of the 
perinuclear space (Fig 1B-a to 1B-d) before being clustered and packaged to initiate 
the budding of the subsequent transport vesicle. To date, no direct extrusion of the 
filaments from the membrane of the nuclear envelope has been observed, and 
intraluminal free ends were clearly identified for some filaments (arrow in Fig 1B-d). 
This suggests that these particles self-assemble inside the perinuclear space by a 
process quite distinct from lipid bilayer vesicle budding. This is supported by 
biochemical analyses that have shown that lipids which are only 25% by weight in the 
SVP have a highly restricted composition and are not organized in a typical bilayer 
configuration, but are instead located on the surface of the particle (Satoh et al., 
2000; Gavilanes et al., 1982). The absence of lipid bilayer in the S SVP was also 
recently confirmed by cryo-EM analysis (Gilbert et al., 2005). 
 
HBV morphogenesis 
 
Unlike some Lentivirinae able to bud through a lipid bilayer without any 
envelope protein (Hourioux et al., 2000), the HBV nucleocapsid budding is strictly 
dependent on the large L protein. The absence of L or its in vitro production under an 
exclusive “e-preS” topology completely abolish the generation of new virions (Bruss 
and Vieluf, 1995). Indeed, the “i-preS” topology of L is obligatory for mature HBV 
nucleocapsid recruitment. A sequence overlapping the 17 C-terminal residues of the 
preS1 domain and the 5 N-terminal residues of the preS2 domain seems to be 
involved in this process (Bruss, 2007; Poisson et al., 1997). Moreover, in order to 
take advantage of all the conditions in the cell, when the ratio between the “i-preS” L 
protein and the nucleocapsid is not optimal, the genomic viral DNA is preferentially 
recycled to the nucleus to amplify the cccDNA stock (Summers et al., 1990). When 
an HBV virion is finally assembled, cryo-EM analyses show that the spike of the core 
dimer does not actually penetrate the lipid envelope but stays in close apposition by 
unclear biophysical links (Seitz et al., 2007; Dryden et al., 2006). A second point of 
interaction between 11 aa residues located at the basis of the core dimer and the 
preS domain of L also plays a role in particle stability (Ponsel and Bruss, 2003). 
It has been generally presumed that the budding of SVP reflect the budding of 
HBV virions. However, although HBV is an enveloped DNA virus, there is growing 
evidence that HBV maturation and egress depend, as for many enveloped RNA 
viruses including Retroviridae or Filoviridae, on intraluminal vesicles of maturing 
endosomes known as multivesicular bodies (MVB) (Fig 2) (Lambert et al., 2007; 
Watanabe et al., 2007; Kian Chua et al., 2006). Usually, MVB are involved in the 
sorting of misfolded and ubiquitinated proteins for their degradation (Slagsvold et al., 
2006 for review). The proteins driving this machinery are grouped into at least three 
oligomeric endosomal sorting complexes required for transport ESCRT-I, -II and -III. 
These complexes are recruited and sequentially assembled to the cytosolic side of a 
late endosome membrane to generate MVB by multiple invaginations. Once the 
protein sorting is terminated, the disassembly of these multimers requires an ATPase 
associated with diverse cellular activities (AAA-type ATPase) named Vps4 (isoforms 
A or B) in humans. It has been previously shown that the ubiquitin-interacting adaptor 
2-adaptin and the Nedd4 ubiquitin ligase interact with the HBV core and L envelope 
proteins, possibly to regulate transport of the viral structures through the budding site 
(Rost et al., 2006; Hartmann-Stuhler and Prange, 2001). Recently, several studies 
have demonstrated that the HBV core and envelope proteins co-localize with 
Vps4A/B and Alix/AIP1 (a functional tie between ESCRT-I and ESCRT-III in 
mammalian cells) and that dominant negative mutants of these host proteins inhibit 
virus release (Lambert et al., 2007; Watanabe et al., 2007). Thus, HBV virions would 
bud into late endosomes or MVB by utilizing ESCRT / Vps4B functions and exit the 
cell by the exosome pathway, as is the case for human immunodeficiency virus type-
1 (HIV-1) in macrophages and human T-lymphoblastic cell lines (Grigorov et al., 
2006). This hypothesis is also supported by the presence of a PPAY sequence 
(residues 129 to 132) in the HBV core protein related to the tetrapeptide late-budding 
(L) domain PPxY (also PTAP or YPDL) found in retrovirus core proteins and involved 
in viral release through the MVB pathway (Slagsvold et al., 2006; Wynne et al., 
1999). How ESCRT mediates viral budding is still unclear. 
 
HBV and SVP assemble in different compartments 
 
Recent studies on HBV morphogenesis have pointed out that the mechanisms 
of the SVP assembly are clearly distinct from those of the enveloped HBV virions and 
independent of the MVB functions. The 2-adaptin, which strongly interacts with the 
HBV L protein does not recognize the HBV small (S) protein, the main component of 
the SVP (Rost et al., 2006). Dominant negative mutants of Alix/AIP1 and/or Vps4A/B 
have no effect on the release of SVP (Lambert et al., 2007; Watanabe et al., 2007). 
Thus, the HBV virion and SVP assembly pathways differ in their requirement for cell 
functions and trafficking routes. Past EM studies of HBV-infected cells have 
documented that the virus assembles in large intracellular compartments (Roingeard, 
2003; Roingeard and Sureau, 1998). Regarding the recent advances in 
understanding HBV morphogenesis, it appears that these large compartments were 
probably late endosomes or MVB. However, long subviral filaments appeared also to 
be formed by a tubular budding at the membrane of the same compartments 
(Roingeard, 2003; Roingeard and Sureau, 1998). Actually, it should be noted that 
these filaments were enriched in L protein. As the L protein interacts with the 2-
adaptin, it is probable that L-rich subviral filaments may assemble into MVB-related 
compartments by a conventional membrane-derived budding and by mechanisms 
quite distinct from those involved in the ER lumen for the HBV S filaments. 
 
Conclusion 
 
Contrary to the preexisting concept, HBV virion and subviral particle 
morphogenesis and traffic seem to involve specific cellular partners and specific 
secretion pathways. EM data obtained on cells producing the HBV S protein alone 
support the hypothesis that MVB functions required for HBV budding are not involved 
in the release of the SVP. The fact that these different particles accomplish their 
assembly in seemingly disparate ways is intriguing. The identity, recruitment, and 
mechanism of action of host factors involved in the various means of HBV and SVP 
assembly will be a challenge for future works. Technological advancements in mass 
spectrometry and large-scale proteome mapping will help to identify new interactions 
between viral and cellular proteins. Visualization of viral particles budding using real 
time high-resolution single-particle light microscopy and by using cryoelectron 
tomography and correlative electron microscopy techniques (Roingeard, 2008) may 
also shed light on these processes. As current therapy against HBV involves drugs 
that induce numerous unwanted side effects and may ultimately be rendered 
ineffective by drug resistant mutants, a better knowledge of these mechanisms might 
be a key factor in the development of more effective and better tolerated new anti-
viral treatments. 
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FIG. 1. EM observation of BHK-21 cells producing the HBV S protein (yellow dot, materials and 
methods described in Patient et al, 2007) and model for the SVP morphogenesis and traffic. Vesicles 
about 0.2 to 0.3 µm in diameter (arrows), packed with 20 nm-large HBV S filaments, are observed 
budding from the nuclear envelope (A-a). After budding, these vesicles are packed with HBV S 
filaments and appear in lengthwise or crosswise sections with a crystal-like structure (A-b). The fusion 
of such vesicles with the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) provides 
the relaxing of these filaments from their crystal-like structure in the ERGIC lumen (A-c). Negative 
staining of the purified intracellular HBV S filaments shows that these filaments tended to dissociate at 
their ends (arrow) into subviral spherical particles (A-d). A careful observation of the cell perinuclear 
space suggestes that nascent filaments are self-assembled in the lumen of this compartment rather 
than by membrane-derived budding (B-a to B-d). For some filaments, intraluminal free ends are 
identified (arrow in B-d). Bars in A-a, A-b, A-c, B-a, B-b and B-c, 200 nm ; Bars in A-d and B-d, 100 nm 
; Nu, nucleus ; Cy, cytosol ; the cellular chaperones potentially involved in the SVP morphogenesis are 
presented as black zig-zag. 
 
 
 
FIG. 2. Model for HBV morphogenesis. On the left is the representation of a typical endocytosis and 
multivesicular bodies (MVB) sorting of an activated membrane protein, e.g. the Epithelium Growth 
Factor Receptor (EGFR). The ubiquitylated (Ub, black square) protein is transported into an early 
endosome to the ESCRT machinery. In MVB, the ubiquitylated receptor is recognized by ESCRT-I (I, 
blue) which immediately recruits additional components of the MVB pathway : ESCRT-II (II, red), 
ESCRT-III (III, green) which is anchored to the MVB membrane by myristylation (zig-zag), Alix/AIP1 
(Alix, purple) and Vps4A/B (brown) which is critical for disassembly of the complex following inward 
budding of intraluminal vesicle (IVL) into the MVB lumen. On the right, the hijacking of MVB sorting 
machinery for HBV morphogenesis is depicted. See text for details. pgRNA, pre-genomic RNA ; 
gDNA, genomic DNA ; the viral reverse-transcriptase located inside the capsid is presented as a black 
heptagon. 
